# Jashvant D Unadkat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4703625/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 207 papers | 10,966 citations | 18482 62 h-index | 42399 92 g-index |
| 211 all docs | 211 docs citations | 211 times ranked | 8046 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Adapting regulatory drugâ€drug interaction guidance to design clinical pharmacokinetic natural productâ€drug interaction studies: A NaPDI Center recommended approach. Clinical and Translational Science, 2022, 15, 322-329. | 3.1 | 3 |
| 2 | Prediction of Hepatobiliary Clearances and Hepatic Concentrations of Transported Drugs in Humans Using Rosuvastatin as a Model Drug. Clinical Pharmacology and Therapeutics, 2022, 112, 593-604. | 4.7 | 3 |
| 3 | Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes. Drug Metabolism and Disposition, 2022, 50, 351-360. | 3.3 | 25 |
| 4 | Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model. Drug Metabolism and Disposition, 2022, 50, 613-623. | 3.3 | 7 |
| 5 | Predicting Regional Respiratory Tissue and Systemic Concentrations of Orally Inhaled Drugs through a Novel PBPK Model. Drug Metabolism and Disposition, 2022, 50, 519-528. | 3.3 | 3 |
| 6 | Characterizing and Quantifying Extrahepatic Metabolism of (âˆ')-Î”<sup>9</sup>-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, (Â±)-11-Hydroxy-Î”<sup>9</sup>-THC (11-OH-THC). Drug Metabolism and Disposition, 2022, 50, 734-740. | 3.3 | 7 |
| 7 | Is the Protein-Mediated Uptake of Drugs by Organic Anion Transporting Polypeptides a Real Phenomenon or an Artifact?. Drug Metabolism and Disposition, 2022, 50, 1132-1141. | 3.3 | 6 |
| 8 | Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective. Pharmaceutical Research, 2022, 39, 1701-1731. | 3.5 | 40 |
| 9 | Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach. Drug Metabolism and Disposition, 2021, 49, 159-168. | 3.3 | 24 |
| 10 | Assessing Transporterâ€Mediated Natural Productâ€Drug Interactions Via In vitroâ€In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail. Clinical Pharmacology and Therapeutics, 2021, 109, 1342-1352. | 4.7 | 21 |
| 11 | Abundance of Pâ€Glycoprotein and Other Drug Transporters at the Human Bloodâ€Brain Barrier in Alzheimerâ€™s Disease: A Quantitative Targeted Proteomic Study. Clinical Pharmacology and Therapeutics, 2021, 109, 667-675. | 4.7 | 35 |
| 12 | Modeling Pharmacokinetic Natural Productâ€“Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach. Pharmacological Reviews, 2021, 73, 847-859. | 16.0 | 8 |
| 13 | In Vitroâ€“toâ€“In Vivo Extrapolation of Transporter-Mediated Renal Clearance: Relative Expression Factor Versus Relative Activity Factor Approach. Drug Metabolism and Disposition, 2021, 49, 470-478. | 3.3 | 17 |
| 14 | Can Cannabinoids Precipitate UGTâ€mediated Drug Interactions?. FASEB Journal, 2021, 35, . | 0.5 | 2 |
| 15 | Abundance of P-glycoprotein and Breast Cancer Resistance Protein Measured by Targeted Proteomics in Human Epileptogenic Brain Tissue. Molecular Pharmaceutics, 2021, 18, 2263-2273. | 4.6 | 11 |
| 16 | Successful Prediction of Human Steadyâ€State Unbound Brainâ€toâ€Plasma Concentration Ratio of Pâ€gp Substrates Using the Proteomicsâ€Informed Relative Expression Factor Approach. Clinical Pharmacology and Therapeutics, 2021, 110, 432-442. | 4.7 | 18 |
| 17 | Development and verification of a linked áµ¸B;<sup>9</sup>-THC/11-OH-THC physiologically-based pharmacokinetic (PBPK) model in healthy, non-pregnant population and extrapolation to pregnant women. Drug Metabolism and Disposition, 2021, 49, DMD-AR-2020-000322. | 3.3 | 12 |
| 18 | Estimating fetal exposure to the Pâ€gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1057-1070. | 2.5 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2). Drug Metabolism and Disposition, 2021, 49, 910-918. | 3.3 | 6 |
| 20 | Prediction of pregnancy-induced changes in secretory and total renal clearance of drugs transported by organic anion transporters. Drug Metabolism and Disposition, 2021, 49, DMD-AR-2021-000557. | 3.3 | 9 |
| 21 | Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation. Drug Metabolism and Disposition, 2021, 49, 919-928. | 3.3 | 25 |
| 22 | Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2020, 107, 96-101. | 4.7 | 6 |
| 23 | Gestational Ageâ€“Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics. Drug Metabolism and Disposition, 2020, 48, 735-741. | 3.3 | 53 |
| 24 | Successful Prediction of Positron Emission Tomographyâ€“Imaged Metformin Hepatic Uptake Clearance in Humans Using the Quantitative Proteomicsâ€“Informed Relative Expression Factor Approach. Drug Metabolism and Disposition, 2020, 48, 1210-1216. | 3.3 | 15 |
| 25 | Pitfalls in Predicting Hepatobiliary Drug Transport Using Human Sandwich-Cultured Hepatocytes. AAPS Journal, 2020, 22, 110. | 4.4 | 7 |
| 26 | Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. Drug Metabolism and Disposition, 2020, 48, 1008-1017. | 3.3 | 50 |
| 27 | Optimized Renal Transporter Quantification by Using Aquaporin 1 and Aquaporin 2 as Anatomical Markers: Application in Characterizing the Ontogeny of Renal Transporters and Its Correlation with Hepatic Transporters in Paired Human Samples. AAPS Journal, 2019, 21, 88. | 4.4 | 33 |
| 28 | Interindividual and Regional Variability in Drug Transporter Abundance at the Human Bloodâ€“Brain Barrier Measured by Quantitative Targeted Proteomics. Clinical Pharmacology and Therapeutics, 2019, 106, 228-237. | 4.7 | 64 |
| 29 | Toward a Consensus on Applying Quantitative Liquid Chromatographyâ€Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper. Clinical Pharmacology and Therapeutics, 2019, 106, 525-543. | 4.7 | 77 |
| 30 | Positron Emission Tomography Imaging of [<sup>11</sup>C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. Clinical Pharmacology and Therapeutics, 2019, 106, 1056-1066. | 4.7 | 51 |
| 31 | A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. , 2019, 201, 25-38. | | 65 |
| 32 | Quantifying Hepatic Enzyme Kinetics of (-)-âˆ†<sup>9</sup>-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling. Drug Metabolism and Disposition, 2019, 47, 743-752. | 3.3 | 18 |
| 33 | Mechanisms of CYP3A Induction During Pregnancy: Studies in HepaRG Cells. AAPS Journal, 2019, 21, 45. | 4.4 | 15 |
| 34 | Drug Concentration Asymmetry in Tissues and Plasma for Small Moleculeâ€“Related Therapeutic Modalities. Drug Metabolism and Disposition, 2019, 47, 1122-1135. | 3.3 | 79 |
| 35 | Hepatic Enzymes Relevant to the Disposition of (âˆ’)-âˆ†<sup>9</sup>-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. Drug Metabolism and Disposition, 2019, 47, 249-256. | 3.3 | 23 |
| 36 | Organic anion transporting polypeptide 2B1 â€“ More than a glass-full of drug interactions. , 2019, 196, 204-215. | | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation. Drug Metabolism and Disposition, 2019, 47, 350-357. | 3.3 | 37 |
| 38 | Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. Drug Metabolism and Disposition, 2018, 46, 189-196. | 3.3 | 43 |
| 39 | Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. Drug Metabolism and Disposition, 2018, 46, 943-952. | 3.3 | 74 |
| 40 | Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. Molecular Pharmacology, 2018, 94, 689-699. | 2.3 | 40 |
| 41 | Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics. Drug Metabolism and Disposition, 2018, 46, 66-74. | 3.3 | 40 |
| 42 | Targeted LC-MS/MS Proteomics-Based Strategy To Characterize in Vitro Models Used in Drug Metabolism and Transport Studies. Analytical Chemistry, 2018, 90, 11873-11882. | 6.5 | 26 |
| 43 | When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions. Drug Metabolism and Disposition, 2018, 46, 1487-1496. | 3.3 | 11 |
| 44 | Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides. Drug Metabolism and Disposition, 2018, 46, 1251-1258. | 3.3 | 14 |
| 45 | Advancing Predictions of Tissue and Intracellular Drug Concentrations Using InÂVitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clinical Pharmacology and Therapeutics, 2018, 104, 865-889. | 4.7 | 92 |
| 46 | The Importance of Incorporating OCT2 Plasma Membrane Expression and Membrane Potential in IVIVE of Metformin Renal Secretory Clearance. Drug Metabolism and Disposition, 2018, 46, 1441-1445. | 3.3 | 38 |
| 47 | Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clinical Pharmacology and Therapeutics, 2018, 104, 890-899. | 4.7 | 185 |
| 48 | Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Productâ€“Drug Interactions: A NaPDI Center Recommended Approach. Drug Metabolism and Disposition, 2018, 46, 1046-1052. | 3.3 | 19 |
| 49 | Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the Model for Passive Placental Permeability Drugs. Drug Metabolism and Disposition, 2017, 45, 939-946. | 3.3 | 75 |
| 50 | Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses. Drug Metabolism and Disposition, 2017, 45, 920-938. | 3.3 | 74 |
| 51 | Optimization and Application of a Biotinylation Method for Quantification of Plasma Membrane Expression of Transporters in Cells. AAPS Journal, 2017, 19, 1377-1386. | 4.4 | 20 |
| 52 | Ontogeny of Hepatic Drug Transporters as Quantified by LCâ€MS/MS Proteomics. Clinical Pharmacology and Therapeutics, 2016, 100, 362-370. | 4.7 | 122 |
| 53 | CYP2D6 Is Inducible by Endogenous and Exogenous Corticosteroids. Drug Metabolism and Disposition, 2016, 44, 750-757. | 3.3 | 26 |
| 54 | Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics. Drug Metabolism and Disposition, 2016, 44, 1752-1758. | 3.3 | 100 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics. Drug Metabolism and Disposition, 2016, 44, 1920-1924. | 3.3 | 114 |
| 56 | Placental ABC Transporters: Biological Impact and Pharmaceutical Significance. Pharmaceutical Research, 2016, 33, 2847-2878. | 3.5 | 84 |
| 57 | Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model. Clinical Pharmacology and Therapeutics, 2016, 100, 413-418. | 4.7 | 79 |
| 58 | The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouse. Biopharmaceutics and Drug Disposition, 2016, 37, 336-344. | 1.9 | 10 |
| 59 | Quantitative Transporter Proteomics by Liquid Chromatography with Tandem Mass Spectrometry: Addressing Methodologic Issues of Plasma Membrane Isolation and Expression-Activity Relationship. Drug Metabolism and Disposition, 2015, 43, 284-288. | 3.3 | 44 |
| 60 | Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2â€“ Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration. Drug Metabolism and Disposition, 2015, 43, 1008-1018. | 3.3 | 39 |
| 61 | The concept of fraction of drug transported (f<sub>t</sub>) with special emphasis on BBB efflux of CNS and antiretroviral drugs. Clinical Pharmacology and Therapeutics, 2015, 97, 320-323. | 4.7 | 16 |
| 62 | Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics. Drug Metabolism and Disposition, 2015, 43, 367-374. | 3.3 | 152 |
| 63 | Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study. Drug Metabolism and Disposition, 2015, 43, 1795-1804. | 3.3 | 37 |
| 64 | Prediction of Gestational Ageâ€“Dependent Induction of In Vivo Hepatic CYP3A Activity Based on HepaRG Cells and Human Hepatocytes. Drug Metabolism and Disposition, 2015, 43, 836-842. | 3.3 | 28 |
| 65 | Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transportâ€”an Update. AAPS Journal, 2015, 17, 65-82. | 4.4 | 463 |
| 66 | Comparison of Heavy Labeled (SIL) Peptide versus SILAC Protein Internal Standards for LC-MS/MS Quantification of Hepatic Drug Transporters. International Journal of Proteomics, 2014, 2014, 1-11. | 2.0 | 16 |
| 67 | Studies on the Role of Metabolic Activation in Tyrosine Kinase Inhibitorâ€“Dependent Hepatotoxicity: Induction of CYP3A4 Enhances the Cytotoxicity of Lapatinib in HepaRG Cells. Drug Metabolism and Disposition, 2014, 42, 162-171. | 3.3 | 40 |
| 68 | Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins. Drug Metabolism and Disposition, 2014, 42, 1301-1313. | 3.3 | 31 |
| 69 | Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. British Journal of Clinical Pharmacology, 2014, 77, 554-570. | 2.4 | 91 |
| 70 | Mechanism of an unusual, but clinically significant, digoxinâ€“bupropion drug interaction. Biopharmaceutics and Drug Disposition, 2014, 35, 253-263. | 1.9 | 16 |
| 71 | Role of (Drug) Transporters in Imaging in Health and Disease. Drug Metabolism and Disposition, 2014, 42, 2007-2015. | 3.3 | 11 |
| 72 | Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochemical Pharmacology, 2014, 92, 690-700. | 4.4 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Pharmacometrics in Pregnancy: An Unmet Need. Annual Review of Pharmacology and Toxicology, 2014, 54, 53-69. | 9.4 | 76 |
| 74 | Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex. Drug Metabolism and Disposition, 2014, 42, 78-88. | 3.3 | 169 |
| 75 | Predicting the Outer Boundaries of P-glycoprotein (P-gp)-Based Drug Interactions at the Human Bloodâ€“Brain Barrier Based on Rat Studies. Molecular Pharmaceutics, 2014, 11, 436-444. | 4.6 | 14 |
| 76 | Protein Abundance of Clinically Relevant Multidrug Transporters along the Entire Length of the Human Intestine. Molecular Pharmaceutics, 2014, 11, 3547-3555. | 4.6 | 211 |
| 77 | Activity of P-Glycoprotein, a Î²-Amyloid Transporter at the Bloodâ€“Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. Journal of Nuclear Medicine, 2014, 55, 1106-1111. | 5.0 | 156 |
| 78 | Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochemical Pharmacology, 2014, 91, 109-118. | 4.4 | 38 |
| 79 | PET Imaging of Oatp-Mediated Hepatobiliary Transport of [11C] Rosuvastatin in the Rat. Molecular Pharmaceutics, 2014, 11, 2745-2754. | 4.6 | 47 |
| 80 | Optimized Approaches for Quantification of Drug Transporters in Tissues and Cells by MRM Proteomics. AAPS Journal, 2014, 16, 634-648. | 4.4 | 90 |
| 81 | Cytochrome P450-Dependent Catabolism of Vitamin K: Ï‰-Hydroxylation Catalyzed by Human CYP4F2 and CYP4F11. Biochemistry, 2013, 52, 8276-8285. | 2.5 | 72 |
| 82 | Modeling Cyclosporine A Inhibition of the Distribution of a P-Glycoprotein PET Ligand, <sup>11</sup>C-Verapamil, into the Maternal Brain and Fetal Liver of the Pregnant Nonhuman Primate: Impact of Tissue Blood Flow and Site of Inhibition. Journal of Nuclear Medicine, 2013, 54, 437-446. | 5.0 | 29 |
| 83 | Effect of Salt Intake on Bioavailability of Mizoribine in Healthy Japanese Males. Drug Metabolism and Pharmacokinetics, 2013, 28, 75-80. | 2.2 | 7 |
| 84 | Effect of Gestational Age on mRNA and Protein Expression of Polyspecific Organic Cation Transporters during Pregnancy. Drug Metabolism and Disposition, 2013, 41, 2225-2232. | 3.3 | 53 |
| 85 | Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for Pâ€based DDIs. Biopharmaceutics and Drug Disposition, 2013, 34, 155-164. | 1.9 | 9 |
| 86 | Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP/ABCG2): Effect of Age, Sex, and Genotype. Journal of Pharmaceutical Sciences, 2013, 102, 787-793. | 3.3 | 99 |
| 87 | A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women. Drug Metabolism and Disposition, 2013, 41, 801-813. | 3.3 | 78 |
| 88 | Induction of Hepatic CYP3A Enzymes by Pregnancy-Related Hormones: Studies in Human Hepatocytes and Hepatic Cell Lines. Drug Metabolism and Disposition, 2013, 41, 281-290. | 3.3 | 51 |
| 89 | Complex Drug Interactions of the HIV Protease Inhibitors 3: Effect of Simultaneous or Staggered Dosing of Digoxin and Ritonavir, Nelfinavir, Rifampin, or Bupropion. Drug Metabolism and Disposition, 2012, 40, 610-616. | 3.3 | 39 |
| 90 | Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2012, 40, 852-855. | 3.3 | 79 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Role of the Equilibrative and Concentrative Nucleoside Transporters in the Intestinal Absorption of the Nucleoside Drug, Ribavirin, in Wild-Type and Ent1(â^'/â^') Mice. Molecular Pharmaceutics, 2012, 9, 2442-2449. | 4.6 | 21 |
| 92 | P-Glycoprotein-Based Loperamideâ€"Cyclosporine Drug Interaction at the Rat Bloodâ€"Brain Barrier: Prediction from In Vitro Studies and Extrapolation to Humans. Molecular Pharmaceutics, 2012, 9, 629-633. | 4.6 | 25 |
| 93 | Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LCâ€MS/MS cocktail assays and RTâ€PCR. Biopharmaceutics and Drug Disposition, 2012, 33, 207-217. | 1.9 | 19 |
| 94 | Substrate- and Species-dependent Inhibition of P-glycoprotein-mediated Transport: Implications for Predicting in vivo Drug Interactions. Journal of Pharmaceutical Sciences, 2011, 100, 3055-3061. | 3.3 | 43 |
| 95 | Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir. Drug Metabolism and Disposition, 2011, 39, 2329-2337. | 3.3 | 62 |
| 96 | Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir. Drug Metabolism and Disposition, 2011, 39, 1070-1078. | 3.3 | 96 |
| 97 | Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharmaceutics and Drug Disposition, 2010, 31, 228-242. | 1.9 | 51 |
| 98 | Positron emission tomography imaging of tissue Pâ€glycoprotein activity during pregnancy in the nonâ€human primate. British Journal of Pharmacology, 2010, 159, 394-404. | 5.4 | 33 |
| 99 | Different Modes of Transport for <sup>3</sup>H-Thymidine, <sup>3</sup>H-FLT, and <sup>3</sup>H-FMAU in Proliferating and Nonproliferating Human Tumor Cells. Journal of Nuclear Medicine, 2010, 51, 1464-1471. | 5.0 | 37 |
| 100 | Increased Glyburide Clearance in the Pregnant Mouse Model. Drug Metabolism and Disposition, 2010, 38, 1403-1406. | 3.3 | 15 |
| 101 | Human Equilibrative Nucleoside Transporter-3 (hENT3) Spectrum Disorder Mutations Impair Nucleoside Transport, Protein Localization, and Stability. Journal of Biological Chemistry, 2010, 285, 28343-28352. | 3.4 | 76 |
| 102 | Impact of Ignoring Extraction Ratio When Predicting Drug-Drug Interactions, Fraction Metabolized, and Intestinal First-Pass Contribution. Drug Metabolism and Disposition, 2010, 38, 1926-1933. | 3.3 | 25 |
| 103 | Testicular Expression of Adora3i2 in Adora3 Knockout Mice Reveals a Role of Mouse A3Ri2 and Human A3Ri3 Adenosine Receptors in Sperm*. Journal of Biological Chemistry, 2010, 285, 33662-33670. | 3.4 | 24 |
| 104 | The Impact and In Vitro to In Vivo Prediction of Transporter-Based Drugâ€"Drug Interactions in Humans. , 2010, , 517-553. | | 4 |
| 105 | The Role of Nucleoside Transporters in the Erythrocyte Disposition and Oral Absorption of Ribavirin in the Wild-Type and Equilibrative Nucleoside Transporter 1(â^'/â^') Mice. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 287-296. | 2.5 | 32 |
| 106 | The Role of the Equilibrative Nucleoside Transporter 1 (ENT1) in Transport and Metabolism of Ribavirin by Human and Wild-Type or Ent1(-/-) Mouse Erythrocytes. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 387-398. | 2.5 | 57 |
| 107 | As in Humans, Pregnancy Increases the Clearance of the Protease Inhibitor Nelfinavir in the Nonhuman Primate Macaca nemestrina. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 1016-1022. | 2.5 | 2 |
| 108 | Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using <sup>11</sup>C-Verapamil in the Brain: Studies of Healthy Humans. Journal of Nuclear Medicine, 2009, 50, 1267-1275. | 5.0 | 127 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Simultaneous PET Imaging of P-Glycoprotein Inhibition in Multiple Tissues in the Pregnant Nonhuman Primate. Journal of Nuclear Medicine, 2009, 50, 798-806. | 5.0 | 47 |
| 110 | Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. American Journal of Physiology - Renal Physiology, 2009, 296, G910-G922. | 3.4 | 120 |
| 111 | Pregnancy Does Not Increase CYP3A or P-Glycoprotein Activity in the Non-Human Primate, Macaca nemestrina. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 586-595. | 2.5 | 4 |
| 112 | Drug interactions at the blood-brain barrier: Fact or fantasy?â˜†. , 2009, 123, 80-104. | | 173 |
| 113 | Effect of Pregnancy on Nitrofurantoin Disposition in Mice. Journal of Pharmaceutical Sciences, 2009, 98, 4306-4315. | 3.3 | 4 |
| 114 | Interplay of Drug Metabolism and Transport: A Real Phenomenon or an Artifact of the Site of Measurement?. Molecular Pharmaceutics, 2009, 6, 1756-1765. | 4.6 | 22 |
| 115 | Hormonal Regulation of BCRP Expression in Human Placental BeWo Cells. Pharmaceutical Research, 2008, 25, 444-452. | 3.5 | 43 |
| 116 | Sensitive and specific LCâ€MS assay for quantification of digoxin in human plasma and urine. Biomedical Chromatography, 2008, 22, 712-718. | 1.7 | 24 |
| 117 | Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. Biochemical Pharmacology, 2008, 75, 1677-1687. | 4.4 | 30 |
| 118 | Rapid solid-phase extraction method to quantify [11C]-verapamil, and its [11C]-metabolites, in human and macaque plasma. Nuclear Medicine and Biology, 2008, 35, 911-917. | 0.6 | 15 |
| 119 | The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse: An Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Molecular Pharmacology, 2008, 73, 949-959. | 2.3 | 99 |
| 120 | In Vitro-to-in Vivo Prediction of P-glycoprotein-Based Drug Interactions at the Human and Rodent Blood-Brain Barrier. Drug Metabolism and Disposition, 2008, 36, 481-484. | 3.3 | 63 |
| 121 | Effect of Pregnancy on Cytochrome P450 3a and P-Glycoprotein Expression and Activity in the Mouse: Mechanisms, Tissue Specificity, and Time Course. Molecular Pharmacology, 2008, 74, 714-723. | 2.3 | 81 |
| 122 | Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells. Molecular Pharmacology, 2008, 73, 845-854. | 2.3 | 104 |
| 123 | New insights into the pharmacology and cytotoxicity of gemcitabine and 2â€²,2â€²-difluorodeoxyuridine. Molecular Cancer Therapeutics, 2008, 7, 2415-2425. | 4.1 | 85 |
| 124 | Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors. Drug Metabolism and Disposition, 2008, 36, 1172-1180. | 3.3 | 102 |
| 125 | Profiling Gene Expression in Human Placentae of Different Gestational Ages: An OPRU Network and UW SCOR Study. Reproductive Sciences, 2008, 15, 866-877. | 2.5 | 121 |
| 126 | Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. American Journal of Physiology - Renal Physiology, 2008, 295, G570-G580. | 3.4 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women. Antimicrobial Agents and Chemotherapy, 2007, 51, 783-786. | 3.2 | 75 |
| 128 | Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions. Drug Metabolism and Disposition, 2007, 35, 1853-1859. | 3.3 | 126 |
| 129 | Inhibition of P-glycoprotein Activity at the Primate Blood-Brain Barrier Increases the Distribution of Nelfinavir into the Brain but Not into the Cerebrospinal Fluid. Drug Metabolism and Disposition, 2007, 35, 1459-1462. | 3.3 | 58 |
| 130 | In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R1809-R1822. | 1.8 | 126 |
| 131 | Breast Cancer Resistance Protein 1 Limits Fetal Distribution of Nitrofurantoin in the Pregnant Mouse. Drug Metabolism and Disposition, 2007, 35, 2154-2158. | 3.3 | 73 |
| 132 | In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharmaceutics and Drug Disposition, 2007, 28, 257-262. | 1.9 | 59 |
| 133 | Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). Journal of Pharmaceutical Sciences, 2007, 96, 3226-3235. | 3.3 | 71 |
| 134 | Validation of a sensitive LCâ€“MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: An OPRU Network study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 860, 34-41. | 2.3 | 20 |
| 135 | Grapefruit Juice, a Glass Full of Drug Interactions?. Clinical Pharmacology and Therapeutics, 2007, 81, 631-633. | 4.7 | 38 |
| 136 | Simultaneous Measurement of In Vivo P-glycoprotein and Cytochrome P450 3A Activities. Journal of Clinical Pharmacology, 2006, 46, 1313-1319. | 2.0 | 33 |
| 137 | Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 704-710. | 2.5 | 87 |
| 138 | Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemotherapy and Pharmacology, 2006, 58, 374-383. | 2.3 | 103 |
| 139 | The role of transporters in drug interactions. European Journal of Pharmaceutical Sciences, 2006, 27, 501-517. | 4.0 | 178 |
| 140 | Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E1295-E1304. | 3.5 | 83 |
| 141 | Regulation of BCRP/ABCG2 expression by progesterone and 17Î²-estradiol in human placental BeWo cells. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E798-E807. | 3.5 | 139 |
| 142 | Changes in Pharmacokinetics of Anti-HIV Protease Inhibitors during Pregnancy: The Role of CYP3A and P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1202-1209. | 2.5 | 29 |
| 143 | Identification of the Mitochondrial Targeting Signal of the Human Equilibrative Nucleoside Transporter 1 (hENT1). Journal of Biological Chemistry, 2006, 281, 16700-16706. | 3.4 | 95 |
| 144 | Electrophysiological Characterization and Modeling of the Structure Activity Relationship of the Human Concentrative Nucleoside Transporter 3 (hCNT3). Molecular Pharmacology, 2006, 69, 1542-1553. | 2.3 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clinical Pharmacology and Therapeutics, 2005, 77, 503-514. | 4.7 | 243 |
| 146 | BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers. Pharmaceutical Research, 2005, 22, 2023-2034. | 3.5 | 104 |
| 147 | Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively. American Journal of Physiology - Cell Physiology, 2005, 288, C39-C45. | 4.6 | 20 |
| 148 | P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 289, R963-R969. | 1.8 | 162 |
| 149 | FUNCTIONAL ANALYSIS OF THE HUMAN VARIANTS OF BREAST CANCER RESISTANCE PROTEIN: I206L, N590Y, AND D620N. Drug Metabolism and Disposition, 2005, 33, 697-705. | 3.3 | 51 |
| 150 | IDENTIFICATION OF CYTOCHROME P450 AND ARYLAMINE N-ACETYLTRANSFERASE ISOFORMS INVOLVED IN SULFADIAZINE METABOLISM. Drug Metabolism and Disposition, 2005, 33, 969-976. | 3.3 | 34 |
| 151 | Residues Met89 and Ser160 in the Human Equilibrative Nucleoside Transporter 1 Affect Its Affinity for Adenosine, Guanosine, S6-(4-Nitrobenzyl)-mercaptopurine Riboside, and Dipyridamole. Molecular Pharmacology, 2005, 67, 837-844. | 2.3 | 36 |
| 152 | Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS Journal, 2005, 7, E118-E133. | 4.4 | 358 |
| 153 | Placental Drug Transporters. Current Drug Metabolism, 2004, 5, 125-131. | 1.2 | 106 |
| 154 | HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2). Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 334-341. | 2.5 | 200 |
| 155 | Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs. Journal of Biological Chemistry, 2004, 279, 4490-4497. | 3.4 | 123 |
| 156 | Pharmacokinetics and Safety of Stavudine in HIVâ€Infected Pregnant Women and Their Infants: Pediatric AIDS Clinical Trials Group Protocol 332. Journal of Infectious Diseases, 2004, 190, 2167-2174. | 4.0 | 36 |
| 157 | Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. Biochemical Pharmacology, 2004, 67, 453-458. | 4.4 | 49 |
| 158 | National Institute on Drug Abuse Conference report on placental proteins, drug transport, and fetal development. American Journal of Obstetrics and Gynecology, 2004, 191, 1858-1862. | 1.3 | 13 |
| 159 | The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clinical Pharmacology and Therapeutics, 2004, 76, 313-322. | 4.7 | 15 |
| 160 | The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clinical Pharmacology and Therapeutics, 2004, 76, 579-587. | 4.7 | 16 |
| 161 | Functional expression of the human breast cancer resistance protein in Pichia pastoris. Biochemical and Biophysical Research Communications, 2004, 320, 730-737. | 2.1 | 33 |
| 162 | Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. Biochemical Journal, 2004, 380, 131-137. | 3.7 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Simultaneous Expression of hCNT1-CFP and hENT1-YFP in Madin-Darby Canine Kidney Cells. Journal of Biological Chemistry, 2002, 277, 37711-37717. | 3.4 | 71 |
| 164 | A Single Glycine Mutation in the Equilibrative Nucleoside Transporter Gene, hENT1, Alters Nucleoside Transport Activity and Sensitivity to Nitrobenzylthioinosine. Biochemistry, 2002, 41, 1512-1519. | 2.5 | 79 |
| 165 | Ontogenic and longitudinal activity of Na<sup>+</sup>-nucleoside transporters in the human intestine. American Journal of Physiology - Renal Physiology, 2001, 280, G475-G481. | 3.4 | 49 |
| 166 | CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. Biopharmaceutics and Drug Disposition, 2001, 22, 157-168. | 1.9 | 22 |
| 167 | More collaboration needed between drug development and imaging communities. Drug Discovery Today, 2001, 6, 514-515. | 6.4 | 1 |
| 168 | Structure-inhibitory profiles of nucleosides for the human intestinal N1 and N2 Na + -nucleoside transporters. Cancer Chemotherapy and Pharmacology, 2000, 46, 394-402. | 2.3 | 29 |
| 169 | Human intestinal es nucleoside transporter: molecular characterization and nucleoside inhibitory profiles. Cancer Chemotherapy and Pharmacology, 2000, 45, 273-278. | 2.3 | 28 |
| 170 | Pharmacokinetics of Azithromycin Administered Alone and with Atovaquone in Human Immunodeficiency Virus-Infected Children. Antimicrobial Agents and Chemotherapy, 1999, 43, 1516-1519. | 3.2 | 9 |
| 171 | In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. American Journal of Obstetrics and Gynecology, 1999, 180, 198-206. | 1.3 | 40 |
| 172 | Enzymes in addition to CYP3A4 and 3A5 mediateN-demethylation of dextromethorphan in human liver microsomes. , 1999, 20, 341-346. | | 13 |
| 173 | Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharmaceutical Research, 1998, 15, 950-952. | 3.5 | 79 |
| 174 | Functional expression of human intestinal Na+-dependent and Na+-independent nucleoside transporters in Xenopus laevis oocytes. Biochemical Pharmacology, 1997, 53, 1909-1918. | 4.4 | 49 |
| 175 | Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. American Journal of Obstetrics and Gynecology, 1996, 174, 856-863. | 1.3 | 19 |
| 176 | Development of a chronically catheterized maternalâ€fetal macaque model to study in utero motherâ€toâ€fetus HIV transmission: A preliminary report. Journal of Medical Primatology, 1996, 25, 218-224. | 0.6 | 14 |
| 177 | Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers*. Clinical Pharmacology and Therapeutics, 1996, 59, 332-340. | 4.7 | 41 |
| 178 | Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo*. Clinical Pharmacology and Therapeutics, 1995, 58, 556-566. | 4.7 | 90 |
| 179 | Simian Immunodeficiency Virus Infection of Macaque Primary Placental Cells. AIDS Research and Human Retroviruses, 1995, 11, 955-961. | 1.1 | 4 |
| 180 | Enzyme kinetic properties of human recombinant arylamine n-acetyltransferase 2 allotypic variants expressed in Escherichia coli. Biochemical Pharmacology, 1995, 50, 697-703. | 4.4 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. Pharmaceutical Research, 1994, 11, 312-317. | 3.5 | 20 |
| 182 | Interaction of zidovudine (azidothymidine) with isoprinosine and probenecid in Macaca fascicularis. Pharmaceutical Research, 1994, 11, 181-183. | 3.5 | 0 |
| 183 | Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: In vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes. Clinical Pharmacology and Therapeutics, 1994, 55, 427-433. | 4.7 | 9 |
| 184 | Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. Clinical Pharmacology and Therapeutics, 1994, 55, 528-534. | 4.7 | 12 |
| 185 | Metabolism of 3â€²-azido-3â€²-deoxythymidine (AZT) in human placentae trophoblasts and Hofbauer cells. Biochemical Pharmacology, 1994, 48, 383-389. | 4.4 | 50 |
| 186 | Maternal-fetal transfer and fetal toxicity of anti-HIV drugs. Placenta, 1994, 15, 67-82. | 1.5 | 4 |
| 187 | Characterization of Macaque placental trophoblast and Hofbauer cell response to Zidovudine. Placenta, 1994, 15, 83-95. | 1.5 | 0 |
| 188 | Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin. Clinical Pharmacology and Therapeutics, 1993, 54, 293-302. | 4.7 | 30 |
| 189 | Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. Clinical Pharmacology and Therapeutics, 1993, 54, 323-328. | 4.7 | 20 |
| 190 | Effect of age on distribution of zidovudine (azidothymidine) into the cerebrospinal fluid of Macaca nemestrina. Pharmaceutical Research, 1993, 10, 1338-1340. | 3.5 | 6 |
| 191 | Transplacental pharmacokinetics of dideoxvinosine (ddI). Placenta, 1992, 13, A50. | 1.5 | 0 |
| 192 | Transplacental transfer and fetal toxicity of dideoxynucleosides. Placenta, 1992, 13, A63. | 1.5 | 5 |
| 193 | A High-Performance Liquid Chromatographic Assay for Dideoxyinosine in Monkey Plasma and Urine. Journal of Pharmaceutical Sciences, 1992, 81, 690-691. | 3.3 | 9 |
| 194 | Pharmacokinetics of acyclovir in the term human pregnancy and neonate. American Journal of Obstetrics and Gynecology, 1991, 164, 569-576. | 1.3 | 138 |
| 195 | Disposition of drugs in cystic fibrosis. II. Hepatic blood flow. Clinical Pharmacology and Therapeutics, 1991, 50, 450-455. | 4.7 | 13 |
| 196 | Disposition of drugs in cystic fibrosis. III. Acetaminophen. Clinical Pharmacology and Therapeutics, 1991, 50, 695-701. | 4.7 | 28 |
| 197 | Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. Clinical Pharmacology and Therapeutics, 1991, 49, 402-409. | 4.7 | 37 |
| 198 | Age Affects the Pharmacokinetics of Inhaled Anesthetics in Humans. Anesthesia and Analgesia, 1991, 73, 310???318. | 2.2 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Problems in Pharmacokinetic Investigations in Patients with HIV Infection. Clinical Pharmacokinetics, 1990, 19, 172-176. | 3.5 | 11 |
| 200 | Simple and effective procedure for complete urine collection from infant macaques (Macaca) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 | 0.7 | 3 |
| 201 | Dose-ranging pharmacokinetics of zidovudine (azidothymidine) in the rat. Pharmaceutical Research, 1989, 06, 734-736. | 3.5 | 16 |
| 202 | Clinical Pharmacokinetics of Zidovudine. Clinical Pharmacokinetics, 1989, 17, 1-9. | 3.5 | 92 |
| 203 | Isoflurane elimination via a bubble oxygenator during extra circulation. Journal of Cardiothoracic and Vascular Anesthesia, 1988, 2, 41-44. | 0.2 | 15 |
| 204 | Bayesian calibration. Analytica Chimica Acta, 1986, 181, 27-36. | 5.4 | 10 |
| 205 | Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clinical Pharmacology and Therapeutics, 1986, 40, 86-93. | 4.7 | 120 |
| 206 | Pitfalls in assessing the radiopurity of tritiated steroids by high-performance liquid chromatography. Journal of Chromatography A, 1983, 261, 298-300. | 3.7 | 10 |
| 207 | Further Considerations of the â€œSingle-Point Single-Doseâ€•Method to Estimate Individual Maintenance Dosage Requirements. Therapeutic Drug Monitoring, 1982, 4, 201-208. | 2.0 | 12 |